Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide versus glimepiride added to metformin for cardiovascular risk markers in type 2 diabetes
2012-000311-87Phase 4Terminated
- Sponsor
- Fundación Fernández-Cruz
- Start
- Feb 2012
- Modality
- Peptides, Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Liraglutide + metformin with Glimepiride + metformin (2 arms). Primary endpoint: Change in circulating endothelial progenitor cells. Started Feb 2012; status: terminated.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-000311-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000311-87.